Cargando…
Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti–neutrophil cytoplasmic antibody–associated vasculitis
Autores principales: | Kant, Sam, Azar, Antoine, Geetha, Duvuru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Society of Nephrology. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607746/ https://www.ncbi.nlm.nih.gov/pubmed/34822874 http://dx.doi.org/10.1016/j.kint.2021.11.012 |
Ejemplares similares
-
Impact of rituximab on humoral response to COVID-19 booster vaccine and antibody kinetics in patients with anti–neutrophil cytoplasmic antibody vasculitis
por: Kant, Sam, et al.
Publicado: (2021) -
Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients
por: Aqeel, Faten, et al.
Publicado: (2022) -
Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis
por: Shah, Shivani, et al.
Publicado: (2017) -
Subcutaneous Immunoglobulin for Antibody Deficiency in Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis
por: Kant, Sam, et al.
Publicado: (2019) -
Bamlanivimab Decreases Severe Outcomes of SARS-CoV-2 Infection in Patients With Antineutrophil Cytoplasmic Antibody Vasculitis
por: Ghosh, Jyotsna, et al.
Publicado: (2021)